Compare Open Text Corporation (OTEX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Sanofi SA — how do they compare? Open Text Corporation trades at $23.7 (market cap $5.61B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 17× Open Text Corporation's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 23 Days and Sanofi SA for 94 Days on average.
| OTEX | SNY | |
|---|---|---|
Market Cap | $5.61B | $95.18B |
Volume | 1,197,475 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $39.69 | $52.34 |
52-Week Low | $20.01 | $39.51 |
Typical Hold Time | 23 Days | 94 Days |
Enterprise Value | $10.63B | $114.48B |
Dividend Yield | 4.82% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $23.24, up 0.43% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 73.74% gross margins and consistent earnings beats, while actively managing debt through recent $1 billion notes offering. Valuation appears attractive with P/E of 9.01 and P/S of 1.1, trading below analyst consensus target of $28.30.
The stock presents value opportunity with discounted multiples and improving cloud momentum, though technical weakness and debt refinancing activities warrant caution. Upside potential exists if earnings growth continues, while execution risks and market sentiment remain key watchpoints for investors.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
